Abstracts Archive - Page 1313 of 2425 - ACR Meeting Abstracts

Abstract Number: 1612 • 2017 ACR/ARHP Annual Meeting
Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort
Javier Narváez¹, Helena Borrell², Fernando Sánchez-Alonso³, Iñigo Rúa-Figueroa⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alén⁷, Jose Luis Andreu⁸, Mariano Andres⁹, Juan José Alegre¹⁰, Ricardo Blanco¹¹, Tatiana Cobo-Ibáñez¹², Gema Bonilla¹³, Alina Boteanu¹⁴, Elvira Diez Alvarez¹⁵, Antonio Fernandez-Nebro¹⁶, Mercedes Freire¹⁷, Marian Gantes¹⁸, Paloma Garcia de la Peña¹⁹, Rosario García-Vicuña²⁰, José Hernández Beiraín²¹, Maria Loreto Horcada²², Jesus Ibañez²³, Antonio Juan²⁴, Nuria Lozano-Rivas²⁵, José Luis Marenco de la Fuente²⁶, Rafael-Benito Melero González²⁷, Carlos Alberto Montilla-Morales²⁸, Mireia Moreno²⁹, Alejandro Olivé³⁰, Maria Teresa Oton Sanchez³¹, Angela Pecondon-Español³², Esther Ruiz Lucea³³, Ana Sánchez Atrio³⁴, Gregorio Santos-Soler³⁵, Francisco Toyos³⁶, Esther Uriarte Isacelaya³⁷, Tomas Ramón Vazquez Rodriguez³⁸, Joan Miquel Nolla² and JM Pego-Reigosa³⁹, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Alava, Spain, ⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹RHEUMATOLOGY, Hospital general universitario de Alicante, Alicante, Spain, ¹⁰Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁵Complejo Asistencial Universitario de León. León. Spain, León, Spain, ¹⁶Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹⁷Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ²⁰Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²¹Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²²Rheumatology, Hospital de Navarra, Pamplona, Spain, ²³Rheumatology, Hospital Povisa, Vigo, Spain, ²⁴Rheumatology, Hospital Son LLatzer, Palma de Mallorca, Spain, ²⁵Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ²⁶Rheumatology, Hospital de Valme, Seville, Spain, ²⁷Rheumatology, EOXI Vigo, Vigo, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ³⁰Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ³¹Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ³²Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³³Rheumatology, Hospital de Basurto, Bilbao, Spain, ³⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³⁵Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ³⁷Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ³⁸Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: To assess the prevalence, risk factors and impact on mortality of primary respiratory disease in a large retrospective cohort. Methods: All adult patients in…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 1614 • 2017 ACR/ARHP Annual Meeting
“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend
Alexa Meara¹, Alexa Meara¹, Juliette Yedimenko², Juliette Yedimenko³, Holly Steigelman², Stacy P. Ardoin⁴ and Ellen Peters⁵, ¹Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Decision Research, Eugene, OR
Background/Purpose: Long-term SLE treatment is often complex due to changing clinical manifestations, disease fluctuation, and frequent medication changes. Treatment can be daunting especially to the…
Abstract Number: 1615 • 2017 ACR/ARHP Annual Meeting
Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus
Nicole Davidson¹, Alexa Meara², Holly Steigelman³, Songzhu Zhao⁴, Guy Brock⁵, Wael Jarjour⁶, Brad H. Rovin⁷, Samir parikh⁴, Hareth M. Madhoun⁸, Lee Hebert⁹, Isabelle Ayoub⁴ and Stacy P. Ardoin¹⁰, ¹The Ohio State University, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University, Columbus, OH, ⁵Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁷Ohio State University Medical Center, Columbus, OH, ⁸Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁹Medicine, Ohio State University Medical Center, Columbus, OH, ¹⁰Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: : Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease which can impact the central nervous system in multiple ways, including development of cognitive…
Abstract Number: 1616 • 2017 ACR/ARHP Annual Meeting
Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Michelle Lopes¹, Laryssa Santos², Luciana Seguro³ and Eloisa Bonfa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Lupus nephritis (LN) usually develops within the first years of Systemic Lupus Erythematosus (SLE) onset and rarely after that. There are scarce studies comparing…
Abstract Number: 1617 • 2017 ACR/ARHP Annual Meeting
Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus
Elaine Kunzler^1,2, Linda S. Hynan³ and Benjamin F. Chong¹, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Northeast Ohio Medical University, Rootstown, OH, ³Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Increased rates of co-existing autoimmune diseases in the systemic lupus erythematosus (SLE) population have been reported.1 Little is known about the prevalence of autoimmune…
Abstract Number: 1618 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery
Lauro Quintanilla-González¹, Gonzalo Torres-Villalobos² and Andrea Hinojosa-Azaola³, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departmen of Experimental Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with increased cardiovascular and infectious complications due to subclinical atherosclerosis, disease activity and treatment-related factors. The…
Abstract Number: 1619 • 2017 ACR/ARHP Annual Meeting
The Impact of Disease Characteristics on Habitual Physical Activity and Sedentary Behavior Among Patients with Systemic Lupus Erythematosus (SLE)
Alexandra Legge¹, Chris Blanchard¹ and John G. Hanly², ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for atherosclerotic cardiovascular disease (ASCVD). As sedentary behavior and lack of physical activity are…
Abstract Number: 1620 • 2017 ACR/ARHP Annual Meeting
Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)
Alexandra Legge¹, Chris Blanchard¹ and John G. Hanly², ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with SLE are at increased risk for atherosclerotic cardiovascular disease (ASCVD). As sedentary behavior and lack of physical activity (PA) have been identified…
Abstract Number: 1621 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By the Automated Neuropsychological Assessment Metrics
Zahi Touma¹, Robin Green², Lesley Ruttan³, Sabrina Lombardi³, Carmela Tartaglia⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁶, Michelle Vitti⁶, Dennisse Bonilla⁶, Joan E. Wither⁵, Marvin J. Fritzler⁷ and Dorcas Beaton⁸, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁴University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: The screening and diagnosis of Cognitive Impairment (CI) in Systemic Lupus Erythematosus (SLE) patients is often delayed. CI diagnosed according to the American College…
Abstract Number: 1622 • 2017 ACR/ARHP Annual Meeting
Associations Among Classification Criteria Items within Systemic Lupus Erythematosus
Zahi Touma¹, Ricard Cervera², Ralph Brinks³, Chiara Tani⁴, Bimba F. Hoyer⁵, Karen H. Costenbader⁶, Valentina Lorenzoni⁷, Gian Sebastiani⁸, Sandra V. Navarra⁹, Eloisa Bonfa¹⁰, Rosalind Ramsey-Goldman¹¹, Sara K. Tedeschi¹², Thomas Doerner¹³, Sindhu Johnson¹⁴, Martin Aringer¹⁵ and Marta Mosca¹⁶, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³Hiller Center for Research in Rheumatology, Dusseldorf, Germany, ⁴University of Pisa, Pisa, Italy, ⁵Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Sant Anna Scuola Universitaria Superiore Pisa, Pisa, Italy, ⁸Ospedale San Camillo, Rome, Italy, ⁹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹³Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany, ¹⁴Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada, ¹⁵Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ¹⁶Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: An EULAR/ACR –sponsored project is currently developing new weighted SLE classification criteria including laboratory/clinical items. Combinations of symptoms appear commonly in SLE arguing against…
Abstract Number: 1623 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By a Comprehensive Neuropsychological Battery
Zahi Touma¹, Robin Green², Carmela Tartaglia³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁶, Michelle Vitti⁶, Dennisse Bonilla⁶, Joan E. Wither⁵, Marvin J. Fritzler⁷ and Dorcas Beaton⁸, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ³University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neurobehavioural manifestation of SLE. In our recent systematic review, the prevalence of CI was 38% (95% CI: 33-43%)…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 1625 • 2017 ACR/ARHP Annual Meeting
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in hospitalized patients. Hospitalized patients with autoimmune disorders are particularly at risk of…
Abstract Number: 1626 • 2017 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Merav Heshin-Bekenstein¹, Emily von Scheven², Aimee O. Hersh³, Laura Trupin⁴, Edward H. Yelin⁴ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset SLE (cSLE) often presents with severe disease, managed with high-dose steroids. However, little is known about differences in long-term steroid toxicity between adults…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].